McKesson’s Jill Strassler, Director, Channel Management, ADM Lab Product Mgmt, joined many of the nation’s top pathologists, laboratory administrators, executives and thought leaders at the 19th annual Executive War College in New Orleans on May 29.
Jill’s session, “Understanding the Newest Rules for Showing Clinical Utility of Molecular Tests and How They Shape Payer Pricing Decisions” helped attendees appreciate how Z-Code Identifiers™ help uniquely identify the rapidly growing number of molecular diagnostics tests; and how Z-Codes, as incorporated into the McKesson Diagnostics Exchange™ national test catalog, help drive decision support and claims auditing strategies in managing diagnostics spend.
Strassler told attendees that the long- and short-term success of molecular diagnostics requires:
- unique test identification,
- transparency regarding appropriate health plan coverage driven by clinical utility
- collaborative pricing.
Ultimately, Strassler said, as the industry looks for the best path to success, determining and sharing clinical utility of each test is critical.
Doug Moeller MD, Medical Director, McKesson Health Solutions and an expert in clinical coding, participated via a remote link, providing examples and color commentary. He pointed out that clinical laboratories have an opportunity through the Diagnostics Exchange process to collaborate with health plans about the evidence-basis of their test, clinical indications, and disease management opportunities.
“Never before have we had such a view of the human blueprint and so many possibilities for curing diseases—maybe even before they happen,” Dr. Moeller said. “But how do payers, clinicians, and laboratories manage all these new tests? That’s one of the biggest challenges facing the industry today.”